[go: up one dir, main page]

FR3123357B1 - Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine - Google Patents

Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine Download PDF

Info

Publication number
FR3123357B1
FR3123357B1 FR2105529A FR2105529A FR3123357B1 FR 3123357 B1 FR3123357 B1 FR 3123357B1 FR 2105529 A FR2105529 A FR 2105529A FR 2105529 A FR2105529 A FR 2105529A FR 3123357 B1 FR3123357 B1 FR 3123357B1
Authority
FR
France
Prior art keywords
seq
conformers
fiber
syn
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2105529A
Other languages
English (en)
Other versions
FR3123357A1 (fr
Inventor
Alix Bouvier-Müller
Frédéric Duconge
Luc Bousset
Ronald Melki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique CEA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Commissariat a lEnergie Atomique CEA, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR2105529A priority Critical patent/FR3123357B1/fr
Priority to US18/564,121 priority patent/US20240240191A1/en
Priority to EP22732601.4A priority patent/EP4347838A1/fr
Priority to PCT/FR2022/050993 priority patent/WO2022248805A1/fr
Priority to JP2023572981A priority patent/JP2024520044A/ja
Publication of FR3123357A1 publication Critical patent/FR3123357A1/fr
Application granted granted Critical
Publication of FR3123357B1 publication Critical patent/FR3123357B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un aptamère caractérisé en ce qu’il possède la capacité de distinguer les conformères de fibres d’α-Syn de type F de la protéine α-Syn (α-Syn) des conformères de fibres d’α-Syn de type R, et en ce qu’il comprend une séquence spécifique d’acide ribonucléique (ARN) modifié ayant au moins 85% d’identité avec une séquence choisie parmi SEQ ID NO :1, SEQ ID NO :2, SEQ ID NO :3, SEQ ID NO :4, SEQ ID NO :5, SEQ ID NO :6, et SEQ ID NO :7, de préférence choisie parmi SEQ ID NO :1 et SEQ ID NO :2. La présente invention concerne en outre une composition ou un kit comprenant au moins de ces aptamères, ainsi que leurs utilisations in vitro. La présente invention porte également sur une méthode de diagnostic de synucléinopathies ainsi qu’une méthode de stratification, de suivi, de pronostic et d’évaluation de l’efficacité d’un traitement d’une synucléinopathie, comprenant l’utilisation d’au moins un aptamère et/ou une composition et/ou un kit susmentionné.
FR2105529A 2021-05-27 2021-05-27 Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine Active FR3123357B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR2105529A FR3123357B1 (fr) 2021-05-27 2021-05-27 Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine
US18/564,121 US20240240191A1 (en) 2021-05-27 2022-05-25 Rna aptamers specific for a-synuclein protein fiber conformers
EP22732601.4A EP4347838A1 (fr) 2021-05-27 2022-05-25 Aptameres arn specifiques de conformeres de fibres de la proteine a-synucleine
PCT/FR2022/050993 WO2022248805A1 (fr) 2021-05-27 2022-05-25 Aptameres arn specifiques de conformeres de fibres de la proteine a-synucleine
JP2023572981A JP2024520044A (ja) 2021-05-27 2022-05-25 α－シヌクレインタンパク質繊維コンフォマーに特異的なＲＮＡアプタマー

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2105529A FR3123357B1 (fr) 2021-05-27 2021-05-27 Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine
FR2105529 2021-05-27

Publications (2)

Publication Number Publication Date
FR3123357A1 FR3123357A1 (fr) 2022-12-02
FR3123357B1 true FR3123357B1 (fr) 2024-04-12

Family

ID=76807799

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2105529A Active FR3123357B1 (fr) 2021-05-27 2021-05-27 Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine

Country Status (5)

Country Link
US (1) US20240240191A1 (fr)
EP (1) EP4347838A1 (fr)
JP (1) JP2024520044A (fr)
FR (1) FR3123357B1 (fr)
WO (1) WO2022248805A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024172061A1 (fr) * 2023-02-17 2024-08-22 国立大学法人京都大学 Aptamère d'arn
WO2025019949A1 (fr) * 2023-07-25 2025-01-30 Carleton University Biocapteur à transistor organique à effet de champ commandé par électrolyte

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657953A1 (fr) 2005-07-19 2007-01-25 University Of Rochester Anticorps d'alpha-synucleine et techniques associees
US11814625B2 (en) 2017-10-23 2023-11-14 Carleton University Aptamers as a therapeutic tool to prevent protein aggregation in neurodegenerative disease

Also Published As

Publication number Publication date
US20240240191A1 (en) 2024-07-18
WO2022248805A1 (fr) 2022-12-01
EP4347838A1 (fr) 2024-04-10
FR3123357A1 (fr) 2022-12-02
JP2024520044A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
Walsh et al. Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis
FR3123357B1 (fr) Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine
Wiseman et al. Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP
Lue et al. TREM 2 Protein Expression Changes Correlate with A lzheimer's Disease Neurodegenerative Pathologies in Post‐Mortem Temporal Cortices
Amin et al. Polyamine biomarkers as indicators of human disease
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
Vergeer et al. Do labour market reforms reduce labour productivity growth? A panel data analysis of 20 OECD countries (1960–2004)
Salzer et al. Neurofilament light as a prognostic marker in multiple sclerosis
Wakasugi et al. Association between hypouricemia and reduced kidney function: a cross-sectional population-based study in Japan
Mascarello et al. Expression and identification of 10 sarcomeric MyHC isoforms in human skeletal muscles of different embryological origin. Diversity and similarity in mammalian species
López-Gallardo et al. CPEO and KSS differ in the percentage and location of the mtDNA deletion
Ehrich et al. Organophosphorus-induced delayed neuropathy
BR112022003663A2 (pt) Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted)
MA51938A1 (fr) Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn
WO2020150290A3 (fr) Procédés et compositions pour restaurer les taux de stmn2
BRPI0406689A (pt) Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório
Rocha-Resende et al. Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury
Emerick et al. Organophosphorus-induced delayed neuropathy: a simple and efficient therapeutic strategy
Freemantle et al. Cholesterol and phospholipids in frontal cortex and synaptosomes of suicide completers: relationship with endosomal lipid trafficking genes
WO2011103330A3 (fr) Nouvelle phosphorylation de la troponine cardiaque i utilisée comme un moniteur de lésion cardiaque
WO2020213969A3 (fr) Biomarqueur pour diagnostiquer un dysfonctionnement des cellules endothéliales cornéennes
Lambe et al. Comparative study of serum calcium, magnesium and zinc levels in preeclampsia and normal pregnancy
O'Rourke et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis
JP2015524653A (ja) 対象における薄皮状態のインビトロ診断方法及び関連用途
Hilliard et al. Force dependent effects of chronic overuse on fibrosis-related genes and proteins in skeletal muscles

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20221202

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5